Dexlansoprazole:

Approved in USA 2009, Canada 2010, Mexico 2011. Patent name: Dexilant by Takeda Pharma,
Already introduced by: Alco, IBN Sina, Incepta, Opsonin, Radiant, Ziska, Popular, Edruc etc.
Market growth: (PMD)

PDV Feasibility:

1. Dual release formula depends on pH.

2. It is possible to formulate in Globex Pharmaceuticals.

Marketing Point:

1. Last longer than lansoprazole, so needs to be taken less time.

2. Longest proton pump inhibitory effect.
3. Can be taken regardless of meal time.

Weakness:

1. High price (30 mg/pc> 9 Tk, 60mg/pc> 16 tk)

2. There is not good evidence that it works better than another PPI.
3. Field marketing team need to be stronger to promote such type of products to targeted
customer.